An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (OMNI)
A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (Ponatinib) in Routine Clinical Practice in the United States (OMNI).
Sponsor: Ariad Pharmaceuticals
Terminated
Business Decision; Insufficient Enrollment
A observational or N/A phase clinical study on Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL, this trial is terminated or withdrawn. The trial is conducted by Ariad Pharmaceuticals and has accumulated 13 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
May 2024 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — May 2024 [monthly]
Terminated
-
Dec 2020 — Jan 2021 [monthly]
Terminated
Status: Recruiting → Terminated
▶ Show 8 earlier versions
-
Apr 2020 — Dec 2020 [monthly]
Recruiting
-
Feb 2020 — Apr 2020 [monthly]
Recruiting
-
Apr 2019 — Feb 2020 [monthly]
Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ariad Pharmaceuticals
- United BioSource, LLC
For direct contact, visit the study record on ClinicalTrials.gov .